- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05306665
PREventing Pain After Surgery (PREPS)
April 19, 2024 updated by: Samantha Meints, Brigham and Women's Hospital
PREventing Pain After Surgery: A Feasibility and Acceptability Study of Acceptance and Commitment Therapy for the Prevention of Chronic Post-surgical Pain (PREPS)
The present study aims to adapt and modify a brief presurgical Acceptance and Commitment Therapy (ACT) intervention aimed at preventing the transition to Chronic Post-Surgical Pain (CPSP) and reducing long-term opioid use.
Investigators will then assess the acceptability, feasibility, and preliminary efficacy of the finalized intervention to prevent the transition to CPSP and reduce post-surgical opioid use six months following lumbar spine surgery.
Finally, investigators will identify psychosocial and psychophysical phenotypes associated with response to this intervention.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Samantha M Meints, PhD
- Phone Number: 6177329014
- Email: smeints@bwh.harvard.edu
Study Contact Backup
- Name: Marise Cornelius, MBA
- Email: mcornelius@bwh.harvard.edu
Study Locations
-
-
Massachusetts
-
Chestnut Hill, Massachusetts, United States, 01467
- Recruiting
- Brigham and Women's Hospital
-
Contact:
- Samantha M Meints
- Phone Number: 617-732-9014
- Email: smeints@bwh.harvard.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
22 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- scheduled to undergo fusion, discectomy, vertebroplasty, kyphoplasty, or foraminotomy
- age 22 and older
- able to communicate fluently in English
Exclusion Criteria:
- inability to complete study procedures due to delirium, dementia, psychosis, or other cognitive impairment
- have a history of severe neurologic movement disorder
- are pregnant or intent to become pregnant during study
- have undergone previous spinal surgery
- have spinal deformity, pseudarthrosis, trauma, infection, or tumor as primary indication for surgery
- have undergone Acceptance and Commitment Therapy in last 2 years
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ACT intervention
Participants assigned to this arm will complete a 1-day ACT workshop followed by a telephone booster after surgery
|
One day in person workshop + telephone booster
|
No Intervention: Treatment As Usual
Participants assigned to this arm will receive treatment as usual.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Interference
Time Frame: 3 months post-op
|
Patient Reported Outcomes Measurement Information System-29 (PROMIS-29); Items are rated from 1-5 and then summed with higher scores indicative of greater pain interference
|
3 months post-op
|
Treatment Helpfulness
Time Frame: Immediately following the ACT workshop
|
Treatment Helpfulness Questionnaire (THQ); Item assesses the perceived helpfulness of the ACT workshop and is rated from -5 (extremely harmful) to 5 (extremely helpful).
|
Immediately following the ACT workshop
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Interference
Time Frame: 1 month post-op
|
Patient Reported Outcomes Measurement Information System-29 (PROMIS-29); Items are rated from 1-5 and then summed with higher scores indicative of greater pain interference
|
1 month post-op
|
Pain Interference
Time Frame: 6 month post-op
|
Patient Reported Outcomes Measurement Information System-29 (PROMIS-29); Items are rated from 1-5 and then summed with higher scores indicative of greater pain interference
|
6 month post-op
|
Opioid dose
Time Frame: 1 month post-op
|
We will assess daily morphine equivalent doses using the ManageMyPain App and confirm via medical record review
|
1 month post-op
|
Opioid dose
Time Frame: 3 months post-op
|
We will assess daily morphine equivalent doses using the ManageMyPain App and confirm via medical record review
|
3 months post-op
|
Pain Intensity
Time Frame: 1 month post-op
|
Patient Reported Outcomes Measurement Information System-29 (PROMIS-29); Values range from 0-10 with higher scores indicating greater pain intensity
|
1 month post-op
|
Pain Intensity
Time Frame: 3 months post-op
|
Patient Reported Outcomes Measurement Information System-29 (PROMIS-29); Values range from 0-10 with higher scores indicating greater pain intensity
|
3 months post-op
|
Pain Intensity
Time Frame: 6 months post-op
|
Patient Reported Outcomes Measurement Information System-29 (PROMIS-29); Values range from 0-10 with higher scores indicating greater pain intensity
|
6 months post-op
|
Opioid dose
Time Frame: 6 months post-op
|
We will assess daily morphine equivalent doses using the ManageMyPain App and confirm via medical record review
|
6 months post-op
|
Treatment Credibility
Time Frame: Immediately following ACT workshop
|
Credibility and Expectancy Questionnaire (CEQ); 3 items are rated 1 (not at all) to 9 (very) to indicate the logic, success, and confidence in the treatment.
Scores are summed with higher scores indicating greater treatment credibility
|
Immediately following ACT workshop
|
Treatment Expectancy
Time Frame: Immediately following ACT workshop
|
Credibility and Expectancy Questionnaire (CEQ); 4 items are used to assess the likelihood of the success of the therapy to reduce pain and improve function.
Scores are summed with a range from 2-28 where higher scores indicate greater expectancy for beneficial treatment outcomes
|
Immediately following ACT workshop
|
Treatment Helpfulness
Time Frame: 1 month post-op
|
Treatment Helpfulness Questionnaire (THQ); Item assesses the perceived helpfulness of the ACT workshop and is rated from -5 (extremely harmful) to 5 (extremely helpful).
|
1 month post-op
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 13, 2023
Primary Completion (Estimated)
August 1, 2026
Study Completion (Estimated)
August 1, 2026
Study Registration Dates
First Submitted
February 23, 2022
First Submitted That Met QC Criteria
March 23, 2022
First Posted (Actual)
April 1, 2022
Study Record Updates
Last Update Posted (Actual)
April 22, 2024
Last Update Submitted That Met QC Criteria
April 19, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022P002302
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The final dataset will be stripped of identifiers prior to release for sharing at the time of publication or shortly thereafter.
The data will then be made available to approved outside collaborators under a data-sharing agreement that provides for (1) commitment to using the data only for research purposes; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying the data after analyses are completed.
Further, the data will be shared via publication and/or public presentations.
IPD Sharing Time Frame
The time of publication or shortly afterward.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Stenosis
-
RTI SurgicalCompletedSpinal Disease | Spinal Instability | Spinal Stenosis Occipito-Atlanto-Axial | Spinal Stenosis Cervical | Spinal Stenosis Cervicothoracic RegionUnited States
-
Azienda Usl di BolognaRecruitingLumbar Spinal Stenosis | Degenerative Lumbar Spinal StenosisItaly
-
Sutherland Medical CenterActive, not recruitingSpinal Stenosis Lumbar | Spinal Canal StenosisPoland
-
Massachusetts General HospitalCompletedLumbar Spinal Stenosis | Thoracic Spinal StenosisUnited States
-
University Hospital, Basel, SwitzerlandKlinik für Radiologie und Nuklearmedizin, University Hospital BaselCompletedLumbar Spinal Stenosis | Symptomatic Lumbar Spinal StenosisSwitzerland
-
Sklifosovsky Institute of Emergency CarePirogov National Medical Surgical Center; Federal State Budgetary Institution... and other collaboratorsActive, not recruitingLumbar Spinal Stenosis | Spinal Stenosis | Spinal FusionRussian Federation
-
Region ZealandRegion SyddanmarkRecruiting
-
Tang-Du HospitalNot yet recruiting
-
Sisli Hamidiye Etfal Training and Research HospitalCompletedLumbar Spinal StenosisTurkey
Clinical Trials on ACT intervention
-
University of CoimbraFundação para a Ciência e a TecnologiaUnknown
-
University of JyvaskylaFinnish Social Insurance InstitutionUnknownStress | Burnout, ProfessionalFinland
-
National Cancer Institute (NCI)RecruitingNeurofibromatosis 1 | Noonan Syndrome | Legius Syndrome | Cardiofaciocutaneous Syndrome | Costello SyndromeUnited States
-
University of EdinburghCompleted
-
Indiana UniversityClaude McNeal Productions; Lilly Endowment, Inc.TerminatedBullying | Social CompetenceUnited States
-
Istituto Auxologico ItalianoCompleted
-
University of JyvaskylaUniversity of Helsinki; University of Eastern Finland; VTT Technical Research... and other collaboratorsCompletedOverweight | Psychological Stress | Metabolic Syndrome Risk FactorsFinland
-
University of Social Sciences and Humanities, WarsawNational Science Centre, PolandNot yet recruitingHematopoietic Cell Transplantation Recipient | Acceptance and Commitment TherapyPoland
-
University of CyprusUniversity of CreteUnknown
-
University of New BrunswickMcGill University; McMaster University; University of Ottawa; Alzheimer Society... and other collaboratorsCompletedDementia | Caregiver Burden | Mental Health | Psychotherapy | Acceptance and Commitment Therapy | Technology | Digital Health | CounsellingCanada